Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

NCT01995578 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT01995578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01995578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
September 27, 2023
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia (aml), myelodysplastic syndromes (mds)